Effects of bisprolol on cardiac function and exercise in patients with heart failure

被引:12
作者
Issa, Victor Sarli [1 ]
Guimaraes, Guilherme Vieira [1 ]
Coimbra Rezende, Marcos Valerio [1 ]
Cruz, Fatima das Dores [1 ]
Moreira, Silvia [1 ]
Ferreira, Ayub [1 ]
Bacal, Fernando [1 ]
Bocchi, Edimar Alcides [1 ]
机构
[1] FMUSP, Inst Coracao, Sao Paulo, Brazil
关键词
bisoprolol; cardiac output; low; exercise; adrenergic beta-antagonists;
D O I
10.1590/S0066-782X2007000300014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the effects of bisoprolol on exercise capacity and ventricular function in patients with heart failure. Methods: Clinical and hemodynamic variables, ventricular function and remodeling, and ergospirometry of patients with heart failure of different etiologies were evaluated before and after the administration of bisoprolol. Results: Twenty-two patients were analyzed; one patient did not tolerate medication and 14 patients reached the study goal. The group consisted of 9 men and 5 women, the mean age was 52 (36-64) years, and patients were followed during 551 days (238-1109). We observed an improvement in NYHA functional class, reduction in resting heart rate (78.8 +/- 8.7 vs 63 +/- 6.4 bpm, p <0.001), increase in left ventricular ejection fraction (31.3 +/- 8.5% vs 39 +/- 14.7%. p=0.043), and a tendency towards improved quality of life scores (31 +/- 20.6 vs 17.8 +/- 14.8. p=0.058). The maximum heart rate dropped during exercise (138.1 +/- 20.2 vs 116.7 +/- 27.1. p=0.01), as did peak oxygen consumption (20.9 +/- 6.8 vs 15.1 +/- 3.5. p < 0.001); no change was observed on the EV/VCO2 slope. The effects were observed for all etiologies, including Chagas' disease. Conclusion: Bisoprolol was safe and well tolerated in patients with heart failure. Bisoprolol therapy improved the symptoms, hemodynamic variables, as well as the cardiac function for all etiologies; however it did not result in improved exercise capacity.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 25 条
[1]  
Bocchi E A, 1998, Arq Bras Cardiol, V71, P169
[2]   Beta-blockers for chronic heart failure: surviving longer but feeling better? [J].
Bolger, AP ;
Al-Nasser, F .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2003, 92 (01) :1-8
[3]  
Chizzola P R, 2000, Arq Bras Cardiol, V74, P233
[4]   The effect of β-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure [J].
Chizzola, PR ;
de Freitas, HFG ;
Marinho, NVS ;
Mansur, JA ;
Meneghetti, JC ;
Bocchi, EA .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 106 (01) :29-34
[5]  
*CRIT COMM NEW YOR, 1994, HEART
[6]  
de Groote P., 2004, Annales de Cardiologie et d'Angeiologie, V53, P167, DOI 10.1016/S0003-3928(04)00069-1
[7]   A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure:: BEST, CIBIS-II, MERIT-HF, and COPERNICUS [J].
Domanski, MJ ;
Krause-Steinrauf, H ;
Massie, BM ;
Deedwania, P ;
Follmann, D ;
Kovar, D ;
Murray, D ;
Oren, R ;
Rosenberg, Y ;
Young, J ;
Zile, M ;
Eichhorn, E .
JOURNAL OF CARDIAC FAILURE, 2003, 9 (05) :354-363
[8]   Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: Analysis with magnetic resonance myocardial tagging [J].
Dubach, P ;
Myers, J ;
Bonetti, P ;
Schertler, T ;
Froelicher, V ;
Wagner, D ;
Scheidegger, M ;
Stuber, M ;
Luchinger, R ;
Schwitter, J ;
Hess, O .
AMERICAN HEART JOURNAL, 2002, 143 (04) :676-683
[9]  
ELSER M, 1997, AM J CARDIOL, V80, pL7